 | Up a level |
van der Maas, Niek G; Versluis, Jurjen; Nasserinejad, Kazem; van Rosmalen, Joost; Pabst, Thomas; Maertens, Johan; Breems, Dimitri; Manz, Markus; Cloos, Jacqueline; Ossenkoppele, Gert J; Floisand, Yngvar; Gradowska, Patrycja; Löwenberg, Bob; Huls, Gerwin; Postmus, Douwe; Pignatti, Francesco; Cornelissen, Jan J (2024). Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial. Blood cancer journal, 14(56) Nature Publishing Group 10.1038/s41408-024-01037-3
Sanz, Jaime; Labopin, Myriam; Pabst, Thomas; Versluis, Jurjen; Van Gorkom, Gwendolyn; Meijer, Ellen; Gedde-Dahl, Tobias; Montoro, Juan; Arcese, William; Pérez-Simón, Jose Antonio; Schaap, Nicolaas; Maertens, Johan; Vrhovac, Radovan; Lanza, Francesco; Gorin, Norbert Claude; Mohty, Mohamad; Ciceri, Fabio (2023). Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 58(11), pp. 1197-1202. Nature Publishing Group 10.1038/s41409-023-02075-4
Bakunina, Katerina; Putter, Hein; Versluis, Jurjen; Koster, Eva A S; van der Holt, Bronno; Manz, Markus G; Breems, Dimitri A; Gjertsen, Bjorn T; Cloos, Jacqueline; Valk, Peter J M; Passweg, Jakob; Pabst, Thomas; Ossenkoppele, Gert J; Löwenberg, Bob; Cornelissen, Jan J; de Wreede, Liesbeth C (2022). The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. Cancer medicine, 11(3), pp. 630-640. Wiley 10.1002/cam4.4392
Shouval, Roni; Labopin, Myriam; Bomze, David; Baerlocher, Gabriela M.; Capria, Saveria; Blaise, Didier; Hänel, Mathias; Forcade, Edouard; Huynh, Anne; Saccardi, Riccardo; Milone, Giuseppe; Zuckerman, Tsila; Reményi, Péter; Versluis, Jurjen; Esteve, Jordi; Gorin, Norbert Claude; Mohty, Mohamad; Nagler, Arnon (2020). Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone marrow transplantation, 55(12), pp. 2244-2253. Springer Nature 10.1038/s41409-020-0936-z
Versluis, Jurjen; Kalin, Burak; Zeijlemaker, Wendelien; Passweg, Jakob; Graux, Carlos; Manz, Markus G; Vekemans, Marie-Christiane; Biemond, Bart J; Legdeur, Marie-Cecile J C; Kooy, Marinus van Marwijk; de Weerdt, Okke; Wijermans, Pierre W; Hoogendoorn, Mels; Bargetzi, Mario J; Kuball, Juergen; Schouten, Harry C; van der Velden, Vincent H J; Janssen, Jeroen J W M; Pabst, Thomas; Lowenberg, Bob; ... (2017). Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. JCO precision oncology, 1, pp. 1-13. American Society of Clinical Oncology 10.1200/PO.17.00078
Versluis, Jurjen; Hazenberg, Carin L E; Passweg, Jakob R; van Putten, Wim L J; Maertens, Johan; Biemond, Bart J; Theobald, Matthias; Graux, Carlos; Kuball, Jurgen; Schouten, Harry C; Pabst, Thomas; Löwenberg, Bob; Ossenkoppele, Gert; Vellenga, Edo; Cornelissen, Jan J (2015). Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. The Lancet. Haematology, 2(10), e427-e436. Elsevier 10.1016/S2352-3026(15)00148-9
